Yahoo Finance

InFlectis BioScience Announces Promising Results for IFB-088 in a Phase 2a Clinical Study in Bulbar-Onset ALS Patients

Nantes, France--(Newsfile Corp. - February 6, 2025) - InFlectis BioScience SAS, a drug discovery company pioneering development of therapeutics harnessing the Integrated Stress Response (ISR) for a ...
People

Mom Battling Rare ALS Pleads for 'Compassionate Use' of New Life-Saving Drug Biogen Won't Give Her

"It's heartbreaking," Lisa Stockman-Mauriello says of being denied access to a drug that could treat her Bulbar ALS Joelle Goldstein is a Senior News Editor on the TV team for PEOPLE Digital. She has ...
Healio

EMA grants orphan drug designation to spinal and bulbar muscular atrophy drug

Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal ...
Yahoo Finance

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

TAIPEI, May 22, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare ...
Business Wire

Nido Biosciences Announces Publication of Collaborative Research Revealing Clinically Meaningful Endpoints for Spinal and Bulbar Muscular Atrophy

BOSTON--(BUSINESS WIRE)--Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, today announced a new publication in Neurology ®, ...
Healio

Positive phase 1 results in trial of novel therapy for spinal and bulbar muscular atrophy

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nido Biosciences has announced positive results from a ...